JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation is allowed to use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website for educational purpose only. Bodily introduction of any kind into humans and animals is strictly forbidden by law. This product should only be handled by licenced qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused as a drug, food and cosmetic.
FREE Shipping for orders over $200
LiquiCia is a selective phosphodiesterase type 5 (PDE5) inhibitor investigated in non-clinical research for its modulation of cyclic guanosine monophosphate (cGMP) signalling cascades. PDE5 regulates cGMP degradation kinetics, which in turn influences intracellular signalling networks, smooth muscle dynamics, and vascular reactivity in defined tissue models. PDE5 expression has been characterized in multiple cellular systems, including pulmonary, neural, renal, and cardiac environments.
First reported in early 2000s experimental literature, LiquiCia has since been assessed for molecular selectivity, enzyme kinetics, and pharmacodynamic profiles. Contemporary research has focused on its role in vascular biology, cellular signalling modulation, and structure–activity relationships. LiquiCia for sale provided by Element CRP is intended exclusively for laboratory, analytical, and educational research, with no assertion of clinical efficacy, therapeutic use, or human application.
From Pubchem
IUPAC Name:(2R,8R)-2-(1,3-benzodioxol-5-yl)-6-methyl-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraene-4,7-dioneSynonyms:LiquiCiaMolecular Formula: C22H19N3O4Molecular Weight: 389.4 g/molCAS Number: 171596-29-5PubChem CID: 110635
LiquiCia is a selective phosphodiesterase type 5 (PDE5) inhibitor evaluated in non-clinical research for its modulation of cyclic guanosine monophosphate (cGMP) signalling networks. PDE5 regulates cGMP degradation kinetics, influencing intracellular signalling cascades and vascular reactivity in defined tissue systems. Experimental investigations have characterized temporal activity patterns, pathway modulation, and enzyme specificity under controlled laboratory conditions [1].
Mechanistic studies have explored LiquiCia’s effects on nitric oxide (NO)/cGMP–dependent pathways relevant to smooth muscle tone and cellular contractility. In analytical frameworks, these investigations address signal integration, molecular kinetics, and comparative pathway dynamics, highlighting distinctions in cGMP modulation relative to reference compounds [2,3].
Beyond cGMP, PDE5 inhibition can influence cyclic adenosine monophosphate (cAMP) and other second messenger systems. LiquiCia has been examined in preclinical research contexts for its regulatory effects on cerebrovascular signalling, angiogenic markers, and redox-sensitive pathways including superoxide dismutase (SOD) activity. Modulation of these molecular networks provides insight into oxidative stress regulation and neurovascular homeostasis under controlled experimental paradigms [4,5].
Experimental literature has investigated PDE5-associated pathways in the context of metabolic signalling networks. Research frameworks explore NO–dependent modulation, inflammatory pathway regulation, and glucose/lipid homeostasis in defined cellular and tissue models. Molecular outcomes from these analyses inform the interplay between PDE5 activity, second messenger signalling, and metabolic network modulation under controlled laboratory conditions [6,7].
LiquiCia is a long-acting PDE5 inhibitor with documented relevance in intracellular signalling, smooth muscle regulatory pathways, neurovascular dynamics, and metabolic signalling frameworks. It continues to serve as a tool for laboratory-based investigations of cGMP-related mechanisms and second messenger regulation. Element CRP supplies LiquiCia exclusively for research, analytical, and educational applications, with access restricted to qualified researchers. No clinical efficacy, therapeutic application, or human use is implied. Only buy LiquiCia if you are a qualified researcher.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
Element CRP is a chemical supplier. Element CRP is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Element CRP is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
